| Literature DB >> 29527321 |
James Watson1,2, Robert M Barker-Davies1,3, Alexander N Bennett1,4, Daniel T P Fong3, Patrick C Wheeler3, Mark Lewis3, Craig Ranson5.
Abstract
OBJECTIVE: Several lower limb tendinopathy treatment modalities involve identification of pathological paratendinous or intratendinous neovascularisation to target proposed co-location of painful neoneuralisation. The ability to reliably locate and assess the degree of neovascularity is therefore clinically important. The Modified Ohberg Score (MOS) is frequently used to determine degree of neovascularity, but reliability has yet to be established among Sport and Exercise Medicine (SEM) consultants. This study aims to determine inter-rater and intra-rater reliability of an SEM consultant cohort when assessing neovascularity using the 5-point MOS.Entities:
Keywords: achilles; tendinopathy; ultrasound
Year: 2018 PMID: 29527321 PMCID: PMC5841524 DOI: 10.1136/bmjsem-2017-000298
Source DB: PubMed Journal: BMJ Open Sport Exerc Med ISSN: 2055-7647
Inclusion and exclusion criteria
| Inclusion criteria | Exclusion criteria |
| 18–60 years of age Localised pain to tendon Pain/stiffness on waking Pain on commencing loaded activity Pain after activity Pain on mobilising after rest | Systemic condition causing inflammatory tendinopathy |
Description of the 5-point Modified Ohberg Score
| Modified Ohberg Score | Description |
| 0 | No vessels |
| 1+ | One vessel anterior to the Achilles |
| 2+ | One to two vessels throughout the tendon |
| 3+ | Three vessels throughout the tendon |
| 4+ | Four or more vessels throughout the tendon |
Figure 1Standardised position for ultrasound imaging of the Achilles tendon.
Figure 2(A)Standardised position for US imaging of the patella tendon (position 1). (B) Standardised position for US imaging of the patella tendon (position 2). US, ultrasound.
Distribution of the Modified Ohberg Scores across all 96 examinations
| Modified Ohberg Score | Number of scores recorded | Percentage of scores recorded |
| 0 | 33 | 34.4 |
| 1+ | 23 | 23.9 |
| 2+ | 16 | 16.7 |
| 3+ | 5 | 5.2 |
| 4+ | 19 | 19.8 |
Agreement between baseline and follow-up scoring
| Follow-up scan | ||||||
| Baseline scan | 0 | 1+ | 2+ | 3+ | 4+ | |
| 0 | 29 | 3 | 0 | 0 | 0 | |
| 1+ | 1 | 19 | 2 | 0 | 1 | |
| 2+ | 0 | 2 | 14 | 0 | 1 | |
| 3+ | 0 | 0 | 0 | 4 | 1 | |
| 4+ | 0 | 0 | 0 | 0 | 18 | |